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Introducing new vaccines: Challenges of
decision making and lessons learned from the
recent Hib vaccine introduction experience
R.A. Hajjeh
NCIRD/OID/CDC, Atlanta, GA, USA
Adoption of new vaccines in developing countries is critical
to reduce child mortality and meeting Millennium Development
Goals. However, such introduction has historically suffered from
signiﬁcant delays, that could be attributed to various factors includ-
ing: lack of recognition of the value of the vaccine (e.g. understand-
ing disease burden, vaccine efﬁcacy, cost-effectiveness and safety;
factors related to weak health systems, such as lack of a decision
making process, immunizations program factors (vaccine logistics,
supply issues), as well as inadequate planning and ﬁnancing; and
policy considerations, such as lack of clear global recommenda-
tions and donor commitment. Recently, The Global Alliance for
Vaccines and Immunizations (GAVI) supported efforts to acceler-
ate the introduction of Hib vaccines in developing countries, which
resulted in signiﬁcant surge of vaccine adoption in these countries.
The experience with Hib vaccines, as well as similar GAVI efforts
to support introduction of the newer pneumococcal and rotavirus
vaccines, provides a strategy for new vaccine adoption that will be
reviewed, providing a useful model to help accelerate the uptake
of other life-saving vaccines. This strategy addresses barriers for
vaccine adoption by focusing on three major areas: communica-
tions to increase awareness about data needs for evidence-based
decisions, research activities to answer key questions thatwill sup-
port vaccine introduction and long term program sustainability,
and coordination with the various stakeholders at global, regional
and country levels to ensure successful program implementation.
http://dx.doi.org/10.1016/j.ijid.2014.03.521
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Vaccine conﬁdence and public trust as drivers
of vaccine failure
H.J. Larson
London School of Hyginene & Tropical Medicine,
London, United Kingdom
An effective vaccine, supportive policy, sustainable ﬁnancing,
human resources, and a willing public are critical elements of
any vaccine success story. A weak point in any one of these
areas can make or break the public health impact of vaccines. In
recent years, the oft taken for granted willingness of the public to
vaccinate themselves or their children has become an increasingly
challenge. An increasing number of vaccine choices, a radically
changed communication environment that has allowed local
vaccine concerns to go quickly viral globally, and societal changes
that have nurtured debate and the right to information and voice,
have converged to create a very different environment around
public conﬁdence in vaccine.
Anti-vaccination movements date back to the 1800s and have
always had an underlying theme of publics wanting a voice. Some
individuals and groups around the world question vaccine safety,
others question the relevance of speciﬁc vaccines, and still oth-
ers have perceived concerns about over-burdening a young child’s
immune-system or have alternative belief systems or notions of
natural immunity. And, sometimes the questions raised are about
vaccine choices andschedules, not a rejectionof vaccines ingeneral.
This presentation will examine modes of better understanding
the drivers of public distrust behind vaccine questioning and con-
sequent vaccine reluctance and refusals. The approaches include
media and social media monitoring for signals of public concerns
and waning vaccine conﬁdence and an assessment of underlying
current and historical factors that could contribute to amplifying
public distrust and have negative consequences for vaccine pro-
grams. Only by understanding the dynamics of distrust and key
drivers of vaccine conﬁdence will it be possible to successfully
achieve relevant vaccine preventable disease control, elimination
and eradication efforts.
http://dx.doi.org/10.1016/j.ijid.2014.03.522
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Tuberculosis vaccines
W. Hanekom
Bill and Melinda Gates Foundation, Seattle, USA
Preventing transmission of the Mycobacterium tuberculosis
(Mtb) is the best strategy to interrupt the global tuberculosis epi-
demic. Vaccination should therefore aimat preventing lung disease
in adults, and at preventing Mtb infection. The current vaccine,
Bacillus Calmette Guerin (BCG), is about 80% effective at preventing
disseminated tuberculosis in youngchildren, butprotectionagainst
adult lung disease is generally poor. Uncontrolled data suggests
that BCG could prevent Mycobacterium tuberculosis (Mtb) infec-
tion in certain settings: these results and proposed next steps will
be discussed. New prime vaccines aim to replace BCG, while other
candidates aim toboost T cell immunityprimedbyBCG, byenviron-
mental mycobacteria or by Mtb infection. Novel approaches that
induce non-natural immunity for prevention of infection will be
discussed. In the settingof aprimedhost response, vaccine-induced
“modulation” of host response may be a more appropriate descrip-
tion of the vaccination goal, compared with “boost”. New results
of protective host responses against disease will be discussed. New
approaches to tuberculosis vaccine clinical trials aim at efﬁciency
and at early up selection of candidates. Examples of how these trials
could be used to learn about protective host responses, which, in
turn, would further inform vaccine development, will be provided.
http://dx.doi.org/10.1016/j.ijid.2014.03.523
